title: The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents.
abstract: BACKGROUND
  Erectile dysfunction (ED) and hypertension are frequent comorbid conditions. The vasodilating properties of type 5 phosphodiesterase inhibitor (PDE5I) are the major concerns for the treatment of ED patients on antihypertensive medications.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of Udenafil [Zydena] (Dong-A, Seoul, Korea), a newly developed PDE5I, for the treatment of ED patients on antihypertensive medication.
  
  
  METHODS
  It was a multicentered, randomized, double-blind, placebo-controlled, fix-dosed clinical trial among 165 ED patients receiving antihypertensive medications. The subjects treated with placebo, 100 mg or 200 mg of Udenafil for 12 weeks were asked to complete the Sexual Encounter Profile (SEP) diary, the International Index of Erectile Function (IIEF), and the Global Assessment Question (GAQ) during the study period.
  
  
  METHODS
  Primary parameter: the change from baseline for IIEF erectile function domain (EFD) score; Secondary parameters: the IIEF Question 3 and 4, SEP Question 2 and 3, the rate of achieving normal erectile function (EFD > or = 26) and the response to GAQ.
  
  
  RESULTS
  Compared to placebo, patients receiving both doses of Udenafil showed significantly improved the IIEF-EFD score. The least squares means for the change from baseline in IIEF-EFD scores were 8.4 and 9.8 for 100 mg and 200 mg Udenafil groups, respectively; those values were significantly higher than that of placebo (2.4, P < 0.0001). Similar results were observed in the comparison of Q3 and Q4 of IIEF, SEP diary and GAQ. Headache and flushing were the most common treatment-emergent adverse events, which were transient and mild-to-moderate in nature. No parameters of efficacy and safety were affected among the subsets stratified according to either the number of antihypertensive medication received or the previous experience of PDE5Is treatment.
  
  
  CONCLUSIONS
  Udenafil significantly improved erectile function among ED patients with hypertensive symptom treated with concomitant antihypertensive medication. The treatment did not increase the frequency or severity of adverse events.
authors.affiliation: Department of Urology, Seoul National University Hospital, 28, Yongon-dong, Chongno-gu, Seoul, 110-744, Korea. jspaick@snu.ac.kr
authors.forename: Jae-Seung
authors.initials: JS
authors.lastname: Paick
authors.forename: Sae Woong
authors.initials: SW
authors.lastname: Kim
authors.forename: Yoon Kyu
authors.initials: YK
authors.lastname: Park
authors.forename: Jae Seog
authors.initials: JS
authors.lastname: Hyun
authors.forename: Nam Cheol
authors.initials: NC
authors.lastname: Park
authors.forename: Sung Won
authors.initials: SW
authors.lastname: Lee
authors.forename: Kwanjin
authors.initials: K
authors.lastname: Park
authors.forename: Ki Hak
authors.initials: KH
authors.lastname: Moon
authors.forename: Woo Sik
authors.initials: WS
authors.lastname: Chung
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D018783:Impotence, Vasculogenic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012725:Sexual Behavior; D013449:Sulfonamides; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D000096926:Benzenesulfonamides
chemical_list: D000959:Antihypertensive Agents; D010726:Phosphodiesterase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C419664:udenafil; D000096926:Benzenesulfonamides